Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: Results and open issues

Internal and Emergency Medicine

Volumn 2, Issue 1, 2007, Pages 3-12

  Bencardino, K ^a   Manzoni, M ^a   Delfanti, S ^a   Riccardi, A ^a   Danova, M ^a   Corazza, G R ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

EGFR; NSCLC; Prognostic and predictive factors; Targeted therapies; TK inhibitors

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ARTICLE; DRUG ANTAGONISM; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MUTATION; PROGNOSIS;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MUTATION; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 34249889302     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-007-0002-5     Document Type: Article

References (58)

1. - (2006) Leading sites of new cancer cases and deaths - 2006 estimates. Cancer facts and figure 2006. American Cancer Society
2. Pfister DG, Johnson DH, Azzoli CG et al (2004) American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22:330-353
3. Brabender J, Danenberg KD, Metzger R et al (2001) Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is con-elated with survival. Clin Cancer Res 7:1850-1855
4. Nicholson RI, Gee JM, Harper ME (2001) EGFR and cancer prognosis. Eur J Cancer 37[Suppl 4]:S9-S15
5. Fukuoka M, Yano S, Giaccone G et al (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21:2237-2246
6. Kris MG, Natale RB, Herbst RS et al (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290:2149-2158
7. Giaccone G, Herbst RS, Manegold C et al (2004) Gefitinib in combination with gemcitabine and cisplatin in advanced non-small cell lung cancer: a phase III trial INTACT-1. J Clin Oncol 22:777-784
8. Herbst RS, Giaccone G, Schiller JH et al (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small cell lung cancer: a phase III trial INTACT-2. J Clin Oncol 22:785-794
9. Perez-Soler R (2004) Phase n clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer. Clin Lung Cancer 6[Suppl 1]:S20-S23
10. Gatzemeier U, Pluzanska A, Szczesna A et al (2004) Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC) [abstract]. ASCO meeting abstracts 22:617 (abstr 7010)
11. Herbst RS, Prager D, Hermann R et al (2005) TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23:5892-5899
12. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132
13. Tamura K, Fukuoka M (2005) Gefitinib in non-small cell lung cancer. Expert Opin Pharmacother 6:985-993
14. Siegel-Lakhai WS, Beijnen JH, Schellens JH (2005) Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa). Oncologist 10:579-589
15. Miller VA, Kris MG, Shah N et al (2004) Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 22:1103-1109
16. Giaccone G (2005) Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. J Clin Oncol 23:3235-3242
17. Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497-1500
18. Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139
19. Pao W, Miller V, Zakowski M et al (2004) EOF receptor gene mutations are common in lung cancers from «never smokers» and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101:13306-13311
20. Kondo M, Yokoyama T, Fukui T et al (2005) Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery. Lung Cancer 50:385-391
21. Rosell R, Ichinose Y, Taron M et al (2005) Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer. Lung Cancer 50:25-33
22. Taron M, Ichinose Y, Rosell R et al (2005) Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res 11:5878-5885
23. Mitsudomi T, Kosaka T, Endoh H et al (2005) Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23:2513-2520
24. Takano T, Ohe Y, Sakamoto H et al (2005) Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 23:6829-6837
25. Han S, Kim T, Hwang PG et al (2005) Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 23:2493-2501
26. Bell DW, Lynch TJ, Haserlat SM et al (2005) Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 23:8081-8092
27. Tomizawa Y, Iijima H, Sunaga N et al (2005) Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small-cell lung cancer. Clin Cancer Res 11:6816-6822
28. Eberhard DA, Johnson BE, Amler LC et al (2005) Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23:5900-5909
29. Riely GJ, Pao W, Pham D et al (2006) Clinical course of patients with non-small-cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 12:839-844
30. Shigematsu H, Gazdar AF (2006) Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 118:257-262
31. Marchetti A, Martella C, Felicioni L et al (2005) EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 23:857-865
32. Asano H, Toyooka S, Tokumo M et al (2006) Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay. Clin Cancer Res 12:43-48
33. Janne PA, Borras AM, Kuang Y et al (2006) A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. Clin Cancer Res 12:751-758
34. Hirsch FR, Varella-Garcia M, Bunn PA Jr et al (2003) Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21:3798-3807
35. Cappuzzo F, Hirsch FR, Rossi E et al (2005) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97:643-655
36. Endo K, Konishi A, Sasaki H et al (2005) Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay. Lung Cancer 50:375-384
37. Johnson BE, Janne PA (2005) Selecting patients for epidermal growth factor receptor inhibitor treatment: a FISH story or a tale of mutations? J Clin Oncol 23:6813-6816
38. Cappuzzo F, Magrini E, Ceresoli CL et al (2004) Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 96:1133-1141
39. Ahrendt SA, Decker PA, Alawi EA et al (2001) Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 92:1525-1530
40. Shigematsu H, Lin L, Takahashi T et al (2005) Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97:339-346
41. Pao W, Wang TY, Riely GJ et al (2005) KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2:e17
42. Sasaki H, Kawano O, Endo K et al (2006) Uncommon V599E BRAF mutations in Japanese patients with lung cancer. J Surg Res 133:203-206
43. Brose MS, Volpe P, Feldman M et al (2002) BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62:6997-7000
44. Toyooka S, Tokumo M, Shigematsu H et al (2006) Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smokers. Cancer Res 66:1371-1375
45. Shibata T, Uryu S, Kokubu A et al (2005) Genetic classification of lung adenocarcinoma based on array-based comparative genomic hybridization analysis: its association with clinicopathologic features. Clin Cancer Res 11:6177-6185
46. Janmaat ML, Rodriguez JA, Gallegos-Ruiz M, Kruyt FA, Giaccone G (2006) Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells. Int J Cancer 118:209-214
47. Cappuzzo F, Varella-Garcia M, Shigematsu H et al (2005) Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small cell lung cancer patients. J Clin Oncol 23:5007-5018
48. Suzuki M, Shigematsu H, Hiroshima K et al (2005) Epidermal growth factor receptor expression status in lung cancer correlates with its mutation. Hum Pathol 36:1127-1134
49. Cappuzzo F, Toschi L, Domenichini I et al (2005) HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients. Br J Cancer 93:1334-1340
50. Pao W, Miller VA, Politi KA et al (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2:e73
51. Kobayashi S, Boggon TJ, Dayaram T et al (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352:786-792
52. Kobayashi S, Ji H, Yuza Y et al (2005) An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res 65:7096-7101
53. Yoshimura N, Kudoh S, Kimura T et al (2006) EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib. Lung Cancer 51:363-368
54. Ando K, Ohmori T, Inoue F et al (2005) Enhancement of sensitivity of tumor necrosis factor alpha in non-small cell lung cancer cells with acquired resistance to gefitinib. Clin Cancer Res 11:8872-8879
55. Shah NP, Tran C, Lee FY et al (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305:399-401
56. Lange T, Muller-Tidow C, Serve H et al (2005) First-line systemic treatment with gefitinib in stage IV non-small cell lung cancer. One Rep 14:1539-1542
57. Lee DH, Han JY, Lee HG et al (2005) Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers. Clin Cancer Res 11:3032-3037
58. Niho S, Kubota K, Goto K et al (2006) First-line single agent treatment with gefitinib in patients with advanced non-small cell lung cancer: a phase II study. J Clin Oncol 24:64-69